HISTORICAL FACTS: Vertex pharmaceuticals - The Untold Story

Two Stickers and a Phone Camera Matched the Lab Test for Cystic Fibrosis, at About a Dollar a Test

A wearable system called CF SWIFT measured sweat chloride in 55 patients at roughly a dollar per test. FDA clearance is still required.

Medical Daily · Aug 18

The World's First CRISPR Gene Therapy Just Got Approved for Children as Young as 2 with Sickle Cell Disease

The FDA on July 1, 2026, expanded Casgevy CRISPR gene therapy to children as young as 2 with sickle cell disease. Here is what families need to know about eligibility and access.

Medical Daily · Jul 23

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.

MarketBeat · Jul 8

Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

Barchart · Feb 17

Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

Barchart · Jan 13

Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).

Benzinga · Dec 8, 2025

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Vertex Pharmaceuticals is set to post its third-quarter results next month, and analysts project a single-digit earnings drop.

Barchart · Oct 16, 2025

ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” on Thursday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes ServiceNow, Inc. (NYSE:NOW), which is down 14% year-to-date.

Benzinga · Oct 3, 2025

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger · Oct 2, 2025

Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?

Vertex Pharmaceuticals has lagged the broader S&P 500 Index over the past year, but Wall Street analysts remain moderately optimistic about the company’s long-term prospects.

Barchart · Sep 8, 2025